Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CVSI, Instadose Pharma And CBD Costs
Instadose sourcing CBD from The Democratic Republic of the Congo, a/k/a DRC or Congo-Kinshasa (and sourcing from Colombia, Argentina and Chile) is not so far fetched.
Anticipating the potential political strife in the DRC, Instadose has purchased and planted Hemp in Colombia, Argentina and Chile, however, the ideal cost of producing and growing cannabis in the DRC makes an intelligent investor wonder what will happen if the world market fell to a price that devalues the entire index by 90% or more? Do we at Instadose drop the price dramatically to crush any and all competition or ”only” by 25% to 30% thereby annexing the entire CBD market for years or decades to come?
iHub itself was founded by Erik and remains and operates ONE COUNTRY AWAY in Nairobi, Kenya
That’s right, not only is iHub located in Senteu Plaza on Galana Road in Nairobi, Kenya, it was founded by Erik there as well.
http://techweez.com/2016/12/08/ihub-set-move-locations-bishop-magua-building-senteu-plaza/
As a matter of fact iHub is known as the unofficial headquarters of Africa's tech movement.
If they’re on the cutting edge of an entire continents tech movement what’s so difficult to believe that Hemp can be grown and CBD sourced from the fertile soil in Sub Saharan Africa?
Land is far less expensive, labor is far less expensive, the climate is perfect and shipping can and is done from the nearest port via boat, far less expensive than by air.
Sub-Saharan Africa has a wide variety of climate zones. The Democratic Republic of the Congo in particular has a dry winter season and a wet summer season perfect for growing Hemp and allowing for free irrigation, just another reason Instadose can and is sorcing Hemp and extracting CBD.
CBD products have been legal in South Africa since they first became available on the market in 1965.
Source: https://www.organica.co.za/product-information/product-guides/cbd-oil-essential-guide/cbd-oil-in-south-africa/
CVSI themselves sources offshore.
That means that before Michael Mona III of CVSI was born CBD Oil was already being extracted, packaged and used as a healing agent known as Elixino. First in Southern Africa and currently worldwide.
Source: https://elixinol.co.za
One would have to take a trip or numerous journeys to this portion of Sub Saharan Africa (as oppossed to the tourist trap of “Fisherman’s Wharf”) in order to verify what can be read in regards to this area.
Besides Erik, I personally know only two people who have done so,
Grant Sanders, CEO of Instadose Pharma and me
These boards are for due diligence discussion of specific stocks not just to ra ra ra whatever you think. An erudite, scholarly, cerebral investor would want to hear all points of view not just those aligned with their own in order to become well educated, knowledgeable and sagacious on the topic as oppossed to continually posting childish acronyms such as ROTFLMAO and LOL.
Notice Who First Picked Up The Story and Reported It
Business Wire - A Berkshire Hathaway Company, CEO Warren Buffet
This is good news as we basically own the Louisiana market with the high mark being N’awlins. Once flower, edibles, extracted oils and recreational products are allowed we’re going to crush it.
Ooooops, CVSI again in THE RED Yes indeed, it’s killing it, the S/P that is. Now I really must run....’night all, keep on “killing it.”
Just as Lauren Lawless is no “famous master chef.” Can anyone here say they’d honestly heard of her prior to using google only to find shes so famous she has 2,000 IG Followers!
Congratulations, you print money. Fantastic! It reminds me of my friend and his family who for many years had the exclusive rights to print currency in Germany. They are all long since retired and I reap the rewards of staying in his 18,000 ft.² Loft in TriBeCa as well as his restored to original condition Key West 5000 ft.² House with its 1400 ft.² guest house. As I usually travel with company and are a fairly private person due to paparazzi being everywhere in my former business (I too are retired) it’s a pleasure when his properties are empty and I have Carte Blanche to stay in them when empty as oppossed to The Mercer in Soho or the Sunset Key Cottages or The Waldorf Casa Marina in Key West. My time in Key West is typically limited as I keep my Azimuth nearby in order to zip over to Havana. Unlike CVSI’s Michael Mona who has so many liens, judgments, enforcement actions and ongoing lawsuits he’s forced to keep his myriad of properties cross collateralized but in a trust in order to protect him from the liens, judgments and existing and yet to come creditors as you can see
Are you not aware of the old saying “don’t try and catch a falling knife as you’re guaranteed to get cut?”
That’s what’s happening with CVSI
CAVEAT EMPTOR
[quoteHow can you have any idea if Management, who are being paid by the stockholders, are accomplishing our goals??? ][/quote]
Either you take the time and effort to do proper due diligence regarding GBLX or not.
It sounds like in your case it’s the latter.
Vandalayind you are absolutely correct. I do know based upon the rules and laws of both FINRA and the SEC There will never be an uplist in the cards for CVSI to NASDAQ or any other stock exchange. it is a breath of fresh air when reading factual information as oppossed to ad hominem attacks. Please continue with your spot on due diligence and the gentlemanly manner in which it’s posted. As we both know it is obvious There will be no uplist for CVSI to NASDAQ or any other stock exchange.
I don’t believe any of the items you’ve mentioned will happen as the management of the stock car no warren Buffets Instead, this company’s management is littered with the following;
Michael Mona Jr. is a serial OTC Fined and Enforced Company Head. He’s been proven by the citations below by the SEC, FINRA and U.S. Federal Court as being dishonest and has far too many liens, judgments, bankruptcies and enforcement actions then can be listed here for CVSI to be uplisted to NASDAQ. Some of these are; this 17 million, eight hundred forty one thousand and six hundred+ dollar judgment;
Michael Mona Jr also filed personal bankruptcy ruled on by Judge Riegle;
Joseph Dowling refused to pay $95,785.00 he legally owed in Federal Income Taxes. He was sued by the creditor, The United States Government represented by the Internal Revenue Service. The Government clearly won their case # 98098644 and he was slapped with the underlying Federal Tax Lien in U.S. Federal Court Final Judgment Hearing # 9198756 which can be seen below;
Joseph Dowling also refused to pay duly owed state taxes in the amount of $8,482.00 in State Court Hearing CAORAC1 in State Court Hearing # 95309318 and was duly convicted and a CA.State Tax Lien was placed upon him and everything he owned as you can clearly see below;
Joseph Dowling also refused to pay a second Ca. State Tax Lien in a case styled CA. Vs Joseph Dowling Hearing # 95218174 - He was convicted and a CA. State Tax Lien was placed against him and everything he owned in the amount of $9,122.00 as can clearly be seen below;
There are numerous other judgments, liens, lawsuits, FINRA and SEC Enforcemnt Actions against Messrs Mona and Dowling,Additionally CVSI’s main financier, John Millar Fife has numerous SEC Enforcement Actions, Suspesions and Lawsuits filed against him. Many of the lawsuits were to disallow the financing as fraudulent, usurious and attempted to clawback the millions upon millions of profits he made or as the suits state allegedly stole from unsuspecting and naive investors. Fife works under numerous corporate veils. In addition to the Iliad LLC he used to loan CVSI money you will also find him making toxic, death spiral convertible dilutive loans under the names; Tonaquint, Tangiers, Chicago Ventures, JVF Holdings, Inter Mountain Capital I Inc and Utah Resources. Many of these can be seen cited at the links below;
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
https://www.sec.gov/litigation/litreleases/2007/lr19972.htm
https://www.sec.gov/litigation/admin/2007/ia-2636.pdf
https://www.sec.gov/Archives/edgar/data/1379699/000114036115001204/doc1.htm
Fife himself was suspended by the SEC in August of 2007 which included his having to pay a hefty fine. The suspension was for a minimum 18 months before he could apply for reinstatement.
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
Sometimes Fife used his wife until she was permanently barred from any position by the SEC in 2015;
https://brokercheck.finra.org/individual/summary/
In the case of Anton and Chia, CVSI’s Former Auditor it’s even more clear; The SEC disciplining CVSI’s accountant and auditor Anton and Chia is stated below as clear fraud, manipulation and subsequent discipline
http://www.lexissecuritiesmosaic.com/gateway/sec/admin-proceeding/34-82206.pdf
Any one of the aforementioned liens, judgments, enforcement actions, lawsuits, claw backs and suspensions are enough to deny an OTC Companies uplist application. Taken in their entirety the prepondence Of evidence is overwhelming. CVSI due to far too many dirty hands, bad actors acting in bad faith will force NASDAQ to deny the uplistapplication. At this point you are probably asking yourself “why haven’t they been denied yet?”
The answer is Nasdaq is entrusted with the authority to preserve and strengthen the quality of and public confidence in its market. Nasdaq stands for integrity and ethical business practices in order to enhance investor confidence, thereby contributing to the financial health of the economy and supporting the capital formation process. Nasdaq Companies, from new public Companies to Companies of international stature, are publicly recognized as sharing these important objectives.
IM-5101-1. Use of Discretionary Authority
To further Companies' understanding of Rule 5101, Nasdaq has adopted this Interpretive Material as a non-exclusive description of the circumstances in which the Rule is generally invoked.
Nasdaq may use its authority under Rule 5101 to deny initial or continued listing to a Company when an individual with a history of regulatory misconduct is associated with the Company. Such individuals are typically an officer, director, Substantial Shareholder (as defined in Rule 5635(e)(3)), or consultant to the Company. In making this determination, Nasdaq will consider a variety of factors, including the nature and severity of the conduct, taken in conjunction with the length of time since the conduct occurred whether the conduct involved fraud or dishonesty; In the cases of Mona, Fife (“Iliad”) and Anton and Chia this applies. Mona committed fraud, paid restitution and voluntarily took a 5 year suspension. Fife (“Iliad”) is even more clear.
However because the company paid the initial $10,000.00 application fee NASDAQ can and will review each and every reason why the application may be denied allowing the company due process to explain, reason and attempt to have themselves excused from such egregious behavior. This occurs during a question and answer period in which NASDAQ may ask for testimony under oath or documentation in support of the companies reasons and excuses. Obviously as witnessed by CVSI’s application this can take an extended period of time. It is generally recognized by those familiar with this process the longer it takes the less like the application will be approved.
All of the aforementioned along with the other questions in the case such as the Food, Drug and Cosmetics Act prohibiting interstate commerce of food containing cannabidiol (CBD) or tetrahydrocannabinol (THC) since it is an active ingredient in an FDA-approved drug, (Epidolex) along with the issue of GW Pharma and their use of CBD in what is now an approved medication may create Anti-Trust Issues.
Indeed In a statement, FDA Commissioner Scott Gottlieb, M.D. says the passage of the U.S. farm bill, now called the Agriculture Improvement Act of 2018 since it is law, does not diminish the agency's regulatory oversight role related to cannabis-containing food and drink.
He stated the FDA will be diligent in monitoring the hemp marketplace to ensure that makers of non-approved products are not making unsubstantiated medical claims.
Also The farm bill is a complex matrix of provisions intended to help farmers already in the business of growing food and fiber for domestic consumption and export. It would also include certain restrictions on imports of food and fiber. These are mostly private enterprises running from small operations of a few acres up to multi billion dollar operations requiring annual financing to the tune of hundreds of millions. Farmers are also, by nature, conservative. They wouldn't, at first, fall all over themselves to commit large amounts of capital to hemp production just to supply some hemp by products to sell to the health and wellness businesses. Which means this is a tiny provision within the total package and not exactly something the politicians who must vote on the bill are deeply concerned with. CVSI and other Hemp, CBD and THC product investors, however, pay no attention to what the politicians are debating about among themselves. Ultimately a bill must please the President, wacko that he is. He has closed the Government for the longest length in the history of the Republic just to close off the entire border with Mexico. CVSI “investors” are trying to simplify what is a very difficult piece of federal legislation with provisions that will have an impact on farming revenues for years to come. Hence that’s why it is called The Agriculture Improvement Act not The “CBD Act” nor The Hemp Act.
The preponderance of the evidence based upon NASDAQ Rule 5101 in addition to the other aforementioned evidence makes an uplist approval highly suspect and highly questionable. Why do you think it’s been 6 months during which other companies have applied and been approved and CVSI hasn’t?
This is true, deep due diligence into this question I personally performed when keeping with my decision to never be a “long” in any OTC Company in which I am not the principal stockholder, financier nor one of the principal stockholders or financiers.
I bought in initially at $.33 and sold my final large holdings at just under $7.00
Since that time I have utilized my day trade account to buy and sell within 24-48 hours $50,000.00 to $60,000.00 of CVSI stock, each time earning between $5,000.00 and $12,500.00 - I would advise anyone else involved in this stock do the same.
Due to all this history along with the reasons I list abovE it is clear there'll be no uplist for CVSI, particularly in the near future but most probably ever. .
You’ll have the opportunity buy CVSI stock at $3.50 soon. However if you have a wee bit of patience you’ll have the opportunity to buy CVSI stock even lower than $3.50 soon. Oooops, breaks over and Rafa’s playing on Center Court. Gotta run, good luck all!
CVSI is not attempting an IPO CVSI is attempting an impossible uplist from the otc to NASDAQ.
It’s nice you like the Steele Herald C-Score. How do you know they’re “professional?” Who are they? Who developed this “C-Score?” Where are they published? Who wrote this article? Are they reputable? We’re they compensated for giving a high score to a company in which the stock has fallen 54.13% in 6 months? Do you know the answer to any of these questions? Due Diligence means looking at all the relevant evidence, not just what feels good.
I’m unaware of this publication however I do know the following numbers are factual as they we’re provided by Mike.......ugghhh I mean CVSI today. They state. CVSI has fallen 54.13% in the past six months dropping below a key support level today;
Due Diligence Regarding CVSI Uplist Amongst Other Relevant Matters,
Michael Mona Jr. is a serial OTC Fined and Enforced Company Head. He’s been proven by the citations below by the SEC, FINRA and U.S. Federal Court as being dishonest and has far too many liens, judgments, bankruptcies and enforcement actions then can be listed here for CVSI to be uplisted to NASDAQ. Some of these are; this 17 million, eight hundred forty one thousand and six hundred+ dollar judgment;
Michael Mona Jr also filed personal bankruptcy ruled on by Judge Riegle;
Joseph Dowling refused to pay $95,785.00 he legally owed in Federal Income Taxes. He was sued by the creditor, The United States Government represented by the Internal Revenue Service. The Government clearly won their case # 98098644 and he was slapped with the underlying Federal Tax Lien in U.S. Federal Court Final Judgment Hearing # 9198756 which can be seen below;
Joseph Dowling also refused to pay duly owed state taxes in the amount of $8,482.00 in State Court Hearing CAORAC1 in State Court Hearing # 95309318 and was duly convicted and a CA.State Tax Lien was placed upon him and everything he owned as you can clearly see below;
Joseph Dowling also refused to pay a second Ca. State Tax Lien in a case styled CA. Vs Joseph Dowling Hearing # 95218174 - He was convicted and a CA. State Tax Lien was placed against him and everything he owned in the amount of $9,122.00 as can clearly be seen below;
There are numerous other judgments, liens, lawsuits, FINRA and SEC Enforcemnt Actions against Messrs Mona and Dowling,Additionally CVSI’s main financier, John Millar Fife has numerous SEC Enforcement Actions, Suspesions and Lawsuits filed against him. Many of the lawsuits were to disallow the financing as fraudulent, usurious and attempted to clawback the millions upon millions of profits he made or as the suits state allegedly stole from unsuspecting and naive investors. Fife works under numerous corporate veils. In addition to the Iliad LLC he used to loan CVSI money you will also find him making toxic, death spiral convertible dilutive loans under the names; Tonaquint, Tangiers, Chicago Ventures, JVF Holdings, Inter Mountain Capital I Inc and Utah Resources. Many of these can be seen cited at the links below;
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
https://www.sec.gov/litigation/litreleases/2007/lr19972.htm
https://www.sec.gov/litigation/admin/2007/ia-2636.pdf
https://www.sec.gov/Archives/edgar/data/1379699/000114036115001204/doc1.htm
Fife himself was suspended by the SEC in August of 2007 which included his having to pay a hefty fine. The suspension was for a minimum 18 months before he could apply for reinstatement.
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
Sometimes Fife used his wife until she was permanently barred from any position by the SEC in 2015;
https://brokercheck.finra.org/individual/summary/
In the case of Anton and Chia, CVSI’s Former Auditor it’s even more clear; The SEC disciplining CVSI’s accountant and auditor Anton and Chia is stated below as clear fraud, manipulation and subsequent discipline
http://www.lexissecuritiesmosaic.com/gateway/sec/admin-proceeding/34-82206.pdf
Any one of the aforementioned liens, judgments, enforcement actions, lawsuits, claw backs and suspensions are enough to deny an OTC Companies uplist application. Taken in their entirety the prepondence Of evidence is overwhelming. CVSI due to far too many dirty hands, bad actors acting in bad faith will force NASDAQ to deny the uplistapplication. At this point you are probably asking yourself “why haven’t they been denied yet?”
The answer is Nasdaq is entrusted with the authority to preserve and strengthen the quality of and public confidence in its market. Nasdaq stands for integrity and ethical business practices in order to enhance investor confidence, thereby contributing to the financial health of the economy and supporting the capital formation process. Nasdaq Companies, from new public Companies to Companies of international stature, are publicly recognized as sharing these important objectives.
IM-5101-1. Use of Discretionary Authority
To further Companies' understanding of Rule 5101, Nasdaq has adopted this Interpretive Material as a non-exclusive description of the circumstances in which the Rule is generally invoked.
Nasdaq may use its authority under Rule 5101 to deny initial or continued listing to a Company when an individual with a history of regulatory misconduct is associated with the Company. Such individuals are typically an officer, director, Substantial Shareholder (as defined in Rule 5635(e)(3)), or consultant to the Company. In making this determination, Nasdaq will consider a variety of factors, including the nature and severity of the conduct, taken in conjunction with the length of time since the conduct occurred whether the conduct involved fraud or dishonesty; In the cases of Mona, Fife (“Iliad”) and Anton and Chia this applies. Mona committed fraud, paid restitution and voluntarily took a 5 year suspension. Fife (“Iliad”) is even more clear.
However because the company paid the initial $10,000.00 application fee NASDAQ can and will review each and every reason why the application may be denied allowing the company due process to explain, reason and attempt to have themselves excused from such egregious behavior. This occurs during a question and answer period in which NASDAQ may ask for testimony under oath or documentation in support of the companies reasons and excuses. Obviously as witnessed by CVSI’s application this can take an extended period of time. It is generally recognized by those familiar with this process the longer it takes the less like the application will be approved.
All of the aforementioned along with the other questions in the case such as the Food, Drug and Cosmetics Act prohibiting interstate commerce of food containing cannabidiol (CBD) or tetrahydrocannabinol (THC) since it is an active ingredient in an FDA-approved drug, (Epidolex) along with the issue of GW Pharma and their use of CBD in what is now an approved medication may create Anti-Trust Issues.
Indeed In a statement, FDA Commissioner Scott Gottlieb, M.D. says the passage of the U.S. farm bill, now called the Agriculture Improvement Act of 2018 since it is law, does not diminish the agency's regulatory oversight role related to cannabis-containing food and drink.
He stated the FDA will be diligent in monitoring the hemp marketplace to ensure that makers of non-approved products are not making unsubstantiated medical claims.
Also The farm bill is a complex matrix of provisions intended to help farmers already in the business of growing food and fiber for domestic consumption and export. It would also include certain restrictions on imports of food and fiber. These are mostly private enterprises running from small operations of a few acres up to multi billion dollar operations requiring annual financing to the tune of hundreds of millions. Farmers are also, by nature, conservative. They wouldn't, at first, fall all over themselves to commit large amounts of capital to hemp production just to supply some hemp by products to sell to the health and wellness businesses. Which means this is a tiny provision within the total package and not exactly something the politicians who must vote on the bill are deeply concerned with. CVSI and other Hemp, CBD and THC product investors, however, pay no attention to what the politicians are debating about among themselves. Ultimately a bill must please the President, wacko that he is. He has closed the Government for the longest length in the history of the Republic just to close off the entire border with Mexico. CVSI “investors” are trying to simplify what is a very difficult piece of federal legislation with provisions that will have an impact on farming revenues for years to come. Hence that’s why it is called The Agriculture Improvement Act not The “CBD Act” nor The Hemp Act.
The preponderance of the evidence based upon NASDAQ Rule 5101 in addition to the other aforementioned evidence makes an uplist approval highly suspect and highly questionable. Why do you think it’s been 6 months during which other companies have applied and been approved and CVSI hasn’t?
This is true, deep due diligence into this question I personally performed when keeping with my decision to never be a “long” in any OTC Company in which I am not the principal stockholder, financier nor one of the principal stockholders or financiers.
I bought in initially at $.33 and sold my final large holdings at just under $7.00
Since that time I have utilized y day trade account to buy and sell within 24-48 hours $50,000.00 to $60,000.00 each time earning between $5,000.00 and $12,500.00 - I would advise anyone else involved in this stock do the same.
Due to all this history along with the reasons I list above I’m confident in saying There'll be no uplist for CVSI, particularly in the near future.
The truth, from the company themselves
Down 54.13% in 6 months. You can deny, cry, ROTFLYAO or LYAO or do any of the things and post any of the millennial, childish sounding logically fallacious ad hominem attacks you like. But a fact is a fact and the above price and percentage changes came from CVSI themselves
U do realize it dropped below $4.25
Yes, Instadose Pharma is well suited to be a far superior company then CVSI as CVSI may very well be the worst company on the OTC. It’s management is with problems like the Mona suspension, fine, and the John Fife / Iliad known OTC toxic financing doesn’t help the CVSI case for uplisting. Uplisting for qualified companies is a simple process that typically takes 4-6 weeks as you can see here;
https://ibb.co/ZL735Ps
Unfortunately for CVSI due to NASDAQ Rule 5101 Uplisting will be denied for association with individuals with a history of regulatory misconduct.
That’s fully applicable in the case of CVSI. Their association with known OTC toxic death spiral financier John Fife (Iliad) is one case.
The PhytosPhere fiasco along with it’s fine of Mona, Mona’s suspension along with the SEC disciplining CVSI’s accountant and auditor Anton and Chia are three other strikes.
http://www.lexissecuritiesmosaic.com/gateway/sec/admin-proceeding/34-82206.pdf
As previously mentioned the CVSI relationship with John Fife (Iliad) a well known OTC toxic death spiral financier is yet another strike. Look at all the lawsuits and SEC regulatory fines and suspensions of Fife.
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
https://www.sec.gov/litigation/litreleases/2007/lr19972.htm
https://www.sec.gov/litigation/admin/2007/ia-2636.pdf
https://www.sec.gov/Archives/edgar/data/1379699/000114036115001204/doc1.htm
Sometimes Fife used his wife until she was permanently barred from any position by the SEC in 2015;
https://brokercheck.finra.org/individual/summary/
Fife himself was suspended by the SEC in August of 2007 which included his having to pay a hefty fine. The suspension was for a minimum 18 months before he could apply for reinstatement.
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
Fife works under numerous corporate veils. In addition to the Iliad LLC he used to loan CVSI money you will also find him making toxic, death spiral convertible dilutive loans under the names; Tonaquint, Tangiers, Chicago Ventures, JVF Holdings, Inter Mountain Capital I Inc and Utah Resources.
Due to all this history along with the reasons I list below I don’t think an uplist is in CVSI’s near future.
The reasons I know in all certainty CVSI will not be accepted to uplist due to what I’ve stated above as well as the following;
(1) The farm bill is a complex matrix of provisions intended to help farmers already in the business of growing food and fiber for domestic consumption and export. It would also include certain restrictions on imports of food and fiber. These are mostly private enterprises running from small operations of a few acres up to multi billion dollar operations requiring annual financing to the tune of hundreds of millions. Farmers are also, by nature, conservative. They wouldn't, at first, fall all over themselves to commit large amounts of capital to hemp production just to supply some hemp by products to sell to the health and wellness businesses. Which means this is a tiny provision within the total package and not exactly something the politicians who must vote on the bill are deeply concerned with. The reefer nuts, however, pay no attention to what the politicians are debating about among themselves. Ultimately a bill must please the President, wacko that he is. He may veto it because he doesn't like the SNAP program. He has just threatened to close off the entire border with Mexico. CVSI “investors” are trying to simplify what is a very difficult piece of federal legislation with provisions that will have an impact on farming revenues for years to come.
(2) NASDAQ Rule 5101. Listing may be denied for association with individuals with a history of regulatory misconduct. Fully applicable.
(3) In a statement, FDA Commissioner Scott Gottlieb, M.D. says the passage of the U.S. farm bill, now called the Agriculture Improvement Act of 2018 since it is law, does not diminish the agency's regulatory oversight role related to cannabis-containing food and drink.
He says the FDA will be diligent in monitoring the hemp marketplace to ensure that makers of non-approved products are not making unsubstantiated medical claims.
Also, the Food, Drug and Cosmetics Act prohibits interstate commerce of food containing cannabidiol (CBD) or tetrahydrocannabinol (THC) since it is an active ingredient in an FDA-approved drugs.
Talking about CVSI on this board will feel so much better once their uplist application is denied and they fall into the trips. What a breath of fresh air it will feel like... it’’ll be like a whole new board. [/b
https://www.marketwatch.com/press-release/canadian-cbd-producers-dramatically-increase-operations-as-revenue-potential-continue-to-explode-2018-11-16
https://gmpnews.net/2018/12/instadose-pharma-become-largest-pharmaceutical-producer-of-cbd-oil/
]
CVSI may very well be the worst company on the OTC. It’s management is with problems like the Mona suspension, fine, and the John Fife / Iliad known OTC toxic financing doesn’t help the CVSI case for uplisting. Uplisting for qualified companies is a simple process that typically takes 4-6 weeks as you can see here;
https://ibb.co/ZL735Ps
Unfortunately for CVSI due to NASDAQ Rule 5101 Uplisting will be denied for association with individuals with a history of regulatory misconduct.
That’s fully applicable in the case of CVSI. Their association with known OTC toxic death spiral financier John Fife (Iliad) is one case.
The PhytosPhere fiasco along with it’s fine of Mona, Mona’s suspension along with the SEC disciplining CVSI’s accountant and auditor Anton and Chia are three other strikes.
http://www.lexissecuritiesmosaic.com/gateway/sec/admin-proceeding/34-82206.pdf
As previously mentioned the CVSI relationship with John Fife (Iliad) a well known OTC toxic death spiral financier is yet another strike. Look at all the lawsuits and SEC regulatory fines and suspensions of Fife.
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
https://www.sec.gov/litigation/litreleases/2007/lr19972.htm
https://www.sec.gov/litigation/admin/2007/ia-2636.pdf
https://www.sec.gov/Archives/edgar/data/1379699/000114036115001204/doc1.htm
Sometimes Fife used his wife until she was permanently barred from any position by the SEC in 2015;
https://brokercheck.finra.org/individual/summary/
Fife himself was suspended by the SEC in August of 2007 which included his having to pay a hefty fine. The suspension was for a minimum 18 months before he could apply for reinstatement.
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
Fife works under numerous corporate veils. In addition to the Iliad LLC he used to loan CVSI money you will also find him making toxic, death spiral convertible dilutive loans under the names; Tonaquint, Tangiers, Chicago Ventures, JVF Holdings, Inter Mountain Capital I Inc and Utah Resources.
Due to all this history along with the reasons I list below I don’t think an uplist is in CVSI’s near future.
The reasons I know in all certainty CVSI will not be accepted to uplist due to what I’ve stated above as well as the following;
(1) The farm bill is a complex matrix of provisions intended to help farmers already in the business of growing food and fiber for domestic consumption and export. It would also include certain restrictions on imports of food and fiber. These are mostly private enterprises running from small operations of a few acres up to multi billion dollar operations requiring annual financing to the tune of hundreds of millions. Farmers are also, by nature, conservative. They wouldn't, at first, fall all over themselves to commit large amounts of capital to hemp production just to supply some hemp by products to sell to the health and wellness businesses. Which means this is a tiny provision within the total package and not exactly something the politicians who must vote on the bill are deeply concerned with. The reefer nuts, however, pay no attention to what the politicians are debating about among themselves. Ultimately a bill must please the President, wacko that he is. He may veto it because he doesn't like the SNAP program. He has just threatened to close off the entire border with Mexico. CVSI “investors” are trying to simplify what is a very difficult piece of federal legislation with provisions that will have an impact on farming revenues for years to come.
(2) NASDAQ Rule 5101. Listing may be denied for association with individuals with a history of regulatory misconduct. Fully applicable.
(3) In a statement, FDA Commissioner Scott Gottlieb, M.D. says the passage of the U.S. farm bill, now called the Agriculture Improvement Act of 2018 since it is law, does not diminish the agency's regulatory oversight role related to cannabis-containing food and drink.
He says the FDA will be diligent in monitoring the hemp marketplace to ensure that makers of non-approved products are not making unsubstantiated medical claims.
Also, the Food, Drug and Cosmetics Act prohibits interstate commerce of food containing cannabidiol (CBD) or tetrahydrocannabinol (THC) since it is an active ingredient in an FDA-approved drugs.
Talking about CVSI on this board will feel so much better once their uplist application is denied and they fall into the trips. What a breath of fresh air it will feel like... it’’ll be like a whole new board.
CVSI about to have competition from the largest market cap company in the sector. 15 billion with enough spare cash on hand to purchase CVSI;
https://seekingalpha.com/article/4233958-canopy-growth-enters-u-s-hemp-industry-bang?app=1&dr=1
Why would they spend 150 million on hemp rather then buy an already existing “alleged market leader”?
Perhaps because the new competition is listed on a real stock exchange yet CVSI can’t and won’t have its NASDAQ Application approved.
SIGO? Only one thing can be said;
CVSI Uplist Application, A Line Item Review
The application CVSI filed on 7/23/2018 was an application to be traded on the NASDAQ Stock Exchange. Therefore any discussion of an uplist must contain the NASDAQ Rules and Requirements For Such An Uplist. These are contained in NASDAQ Rule 5101
5100. Nasdaq's Regulatory Authority
5101. Preamble to the Rule 5100 Series
Nasdaq is entrusted with the authority to preserve and strengthen the quality of and public confidence in its market. Nasdaq stands for integrity and ethical business practices in order to enhance investor confidence, thereby contributing to the financial health of the economy and supporting the capital formation process. Nasdaq Companies, from new public Companies to Companies of international stature, are publicly recognized as sharing these important objectives.
Nasdaq, therefore, in addition to applying the enumerated criteria set forth in the Rule 5000 Series, has broad discretionary authority over the initial and continued listing of securities in Nasdaq in order to maintain the quality of and public confidence in its market, to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, and to protect investors and the public interest. Nasdaq may use such discretion to deny initial listing, apply additional or more stringent criteria for the initial or continued listing of particular securities, or suspend or delist particular securities based on any event, condition, or circumstance that exists or occurs that makes initial or continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though the securities meet all enumerated criteria for initial or continued listing on Nasdaq. In all circumstances where the Listing Qualifications Department (as defined in Rule 5805) exercises its authority under Rule 5101, the Listing Qualifications Department shall issue a Staff Delisting Determination under Rule 5810(c)(1), and in all circumstances where an Adjudicatory Body (as defined in Rule 5805) exercises such authority, the use of the authority shall be described in the written decision of the Adjudicatory Body.
Amended June 16, 2009 (SR-NASDAQ-2009-052).
IM-5101-1. Use of Discretionary Authority
To further Companies' understanding of Rule 5101, Nasdaq has adopted this Interpretive Material as a non-exclusive description of the circumstances in which the Rule is generally invoked.
Nasdaq may use its authority under Rule 5101 to deny initial or continued listing to a Company when an individual with a history of regulatory misconduct is associated with the Company. Such individuals are typically an officer, director, Substantial Shareholder (as defined in Rule 5635(e)(3)), or consultant to the Company. In making this determination, Nasdaq will consider a variety of factors, including:
• the nature and severity of the conduct, taken in conjunction with the length of time since the conduct occurred;
• whether the conduct involved fraud or dishonesty; In the cases of Mona, Fife (“Iliad”) and Anton and Chia this applies. Mona committed fraud, paid restitution and voluntarily took a 5 year suspension. Fife (“Iliad”) is even more clear. Have a look;
As previously mentioned the CVSI relationship with John Fife (Iliad) a well known OTC toxic death spiral financier is yet another strike. Look at all the lawsuits and SEC regulatory fines and suspensions of Fife.
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
https://www.sec.gov/litigation/litreleases/2007/lr19972.htm
https://www.sec.gov/litigation/admin/2007/ia-2636.pdf
https://www.sec.gov/Archives/edgar/data/1379699/000114036115001204/doc1.htm
Sometimes Fife used his wife until she was permanently barred from any position by the SEC in 2015;
https://brokercheck.finra.org/individual/summary/
Fife himself was suspended by the SEC in August of 2007 which included his having to pay a hefty fine. The suspension was for a minimum 18 months before he could apply for reinstatement.
https://www.sec.gov/litigation/litreleases/2007/lr20250.htm
Fife works under numerous corporate veils. In addition to the Iliad LLC he used to loan CVSI money you will also find him making toxic, death spiral convertible dilutive loans under the names; Tonaquint, Tangiers, Chicago Ventures, JVF Holdings, Inter Mountain Capital I Inc and Utah Resources.
In the case of Anton and Chia it’s even more clear; The SEC disciplining CVSI’s accountant and auditor Anton and Chia is stated below as this clear fraud and discipline
http://www.lexissecuritiesmosaic.com/gateway/sec/admin-proceeding/34-82206.pdf
• whether the conduct was securities-related; It was
• whether the investing public was involved; They were
• how the individual has been employed since the violative conduct; Taking the “emeritus position and placing his son in his position clearly violates this section
• whether there are continuing sanctions (either criminal or civil) against the individual; There are, a 5 year suspension
• whether the individual made restitution; Did he?
• whether the Company has taken effective remedial action; and
• the totality of the individual's relationship to the Company, giving consideration to:
º the individual's current or proposed position; Again, the “Emeritus” position and placing his son in his (Mona III’s position making Mona Jr violates this section
º the individual's current or proposed scope of authority; Yet again, the “Emeritus” position and placing his son in his (Mona III’s position making Mona Jr violates this section[/b
º the extent to which the individual has responsibility for financial accounting or reporting; and
º the individual's equity interest. Hes the largest shareholder, he’s taken the “Emeritus position and he’s placed his son in his prior position. This is certainly not “clean hands” nor “hands off.”
Based on this review, Nasdaq may determine that the regulatory history rises to the level of a public interest concern, but may also consider whether remedial measures proposed by the Company, if taken, would allay that concern. Examples of such remedial measures could include any or all of the following, as appropriate:
• the individual's resignation from officer and director positions, and/or other employment with the Company;
• divestiture of stock holdings; He hasn’t (Mona III
• terminations of contractual arrangements between the Company and the individual; or (This is the first clear yes.
• the establishment of a voting trust surrounding the individual's shares. Oooooops, back to NO (Mona III
Nasdaq staff is willing to discuss with Companies, on a case-by-case basis, what remedial measures may be appropriate to address public interest concerns, and for how long such remedial measures would be required. Alternatively, Nasdaq may conclude that a public interest concern is so serious that no remedial measure would be sufficient to alleviate it. In the event that Nasdaq staff denies initial or continued listing based on such public interest considerations, the Company may seek review of that determination through the procedures set forth in the Rule 5800 Series. On consideration of such appeal, a listing qualifications panel comprised of persons independent of Nasdaq may accept, reject or modify the staff's recommendations by imposing conditions.
Nasdaq may also use its discretionary authority, for example, when a Company files for protection under any provision of the federal bankruptcy laws or comparable foreign laws, when a Company's independent accountants issue a disclaimer opinion on financial statements required to be audited, or when financial statements do not contain a required certification.
In addition, pursuant to its discretionary authority, Nasdaq will review the Company's past corporate governance activities. This review may include activities taking place while the Company is listed on Nasdaq or an exchange that imposes corporate governance requirements, as well as activities taking place after a formerly listed company is no longer listed on Nasdaq or such an exchange. Based on such review, and in accordance with the Rule 5800 Series, Nasdaq may take any appropriate action, including placing restrictions on or additional requirements for listing, or denying listing of a security, if Nasdaq determines that there have been violations or evasions of such corporate governance standards. Such determinations will be made on a case-by-case basis as necessary to protect investors and the public interest.
Although Nasdaq has broad discretion under Rule 5101 to impose additional or more stringent criteria, the Rule does not provide a basis for Nasdaq to grant exemptions or exceptions from the enumerated criteria for initial or continued listing, which may be granted solely pursuant to rules explicitly providing such authority.
Adopted March 12, 2009 (SR-NASDAQ-2009-018); amended June 16, 2009 (SR-NASDAQ-2009-052).
In addition you have the FDA Issue as stated by FDA Commissoner Scott Gottlieb, M.D. says the passage of the U.S. farm bill, now called the Agriculture Improvement Act of 2018 since it is law, does not diminish the agency's regulatory oversight role related to cannabis-containing food and drink.
He says the FDA will be diligent in monitoring the hemp marketplace to ensure that makers of non-approved products are not making unsubstantiated medical claims.
Also, the Food, Drug and Cosmetics Act prohibits interstate commerce of food containing cannabidiol (CBD) or tetrahydrocannabinol (THC) since it is an active ingredient in an FDA-approved drugs
You also have the issue of GW and their use of CBD in what is now an approved medication creating Anti-Trust Issues.
The preponderance of the evidence based upon NASDAQ Rule 5101 in addition to other aforementioned evidence makes an uplist approval highly suspect and highly questionable. Why do you think it’s been 6 months, other companies have applied and been approved and CVSI hasn’t?
Due to all this history along with the reasons I list above I’m confident in saying they’ll be no uplist for CVSI, particularly in the near future.
CVSI Uplist yet?
NO
crushing it?
No, red again today
CVSI is a big winner for anyone who got in more than 6 months ago with a significant amount of shares. Each day that ticks bye and the price goes sideways is another day some begin to wonder if they shouldn't peel off a few shares, pay the capital gains, and put it into another opportunity.
CVSI isn't advancing in six months from four dollars fifty to forty five, much less four hundred fifty.